Global Peanut Allergy Clinical Trials Review, 2020 - By Region, Country, Trial Status, Trial Phase, Sponsor Type & End Point Status - ResearchAndMarkets.com

DUBLIN--()--The "Peanut Allergy Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Summary

This clinical trial report, Peanut Allergy Global Clinical Trials Review, H1, 2020" provides an overview of Peanut Allergy Clinical trials scenario. This report provides top line data relating to the clinical trials on Peanut Allergy. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the publisher's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Clinical Trials by G7 Countries: Proportion of Peanut Allergy to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Peanut Allergy Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Peanut Allergy
  • Nov 14, 2019: Antibody injection stops peanut allergy for 2 to 6 weeks, Stanford-led study shows
  • Nov 08, 2019: AR101 demonstrates consistent efficacy and safety in new analysis at ACAAI comparing PALISADE and ARTEMIS phase 3 clinical data
  • Nov 08, 2019: New data presented at ACAAI 2019 show importance of clinical history in identifying AR101-eligibile patients for PALISADE study without a food challenge
  • Nov 07, 2019: POISED study supports risk of cessation of oral immunotherapy for peanut allergy; PACE study indicates safer peanut allergy treatment approaches are needed
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact Us
  • Source

Companies Mentioned

  • Aimmune Therapeutics Inc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • AnaptysBio Inc
  • Food Allergy Research & Education Inc
  • Novartis AG
  • Sanofi
  • Aravax Pty Ltd
  • Astellas Pharma Inc
  • Droege International Group AG

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1mtx71

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900